Wednesday, October 29, 2025 4:06:57 PM
Dew - is this correct? If so, you might be wrong -
Has an accelerated approval for a viral disease been granted?
Yes, accelerated approval for viral diseases has happened, most notably for treatments for HIV/AIDS. In fact, the U.S. Food and Drug Administration (FDA) created the accelerated approval pathway in 1992 specifically in response to the HIV/AIDS epidemic and pressure from patient advocates.
The FDA also used this process for antivirals and vaccines during the COVID-19 pandemic and other infectious disease outbreaks.
Accelerated approval for HIV/AIDS
During the HIV/AIDS crisis, patient activists demanded faster access to promising new therapies for a life-threatening disease with no adequate treatment options.
Instead of waiting for long-term clinical trials that measure survival, the FDA granted accelerated approval for HIV drugs based on surrogate endpoints, such as a reduction in viral load.
This approach allowed life-saving antiretroviral therapies to reach patients years earlier and led to a dramatic reduction in the U.S. HIV/AIDS death rate.
Has an accelerated approval for a viral disease been granted?
Yes, accelerated approval for viral diseases has happened, most notably for treatments for HIV/AIDS. In fact, the U.S. Food and Drug Administration (FDA) created the accelerated approval pathway in 1992 specifically in response to the HIV/AIDS epidemic and pressure from patient advocates.
The FDA also used this process for antivirals and vaccines during the COVID-19 pandemic and other infectious disease outbreaks.
Accelerated approval for HIV/AIDS
During the HIV/AIDS crisis, patient activists demanded faster access to promising new therapies for a life-threatening disease with no adequate treatment options.
Instead of waiting for long-term clinical trials that measure survival, the FDA granted accelerated approval for HIV drugs based on surrogate endpoints, such as a reduction in viral load.
This approach allowed life-saving antiretroviral therapies to reach patients years earlier and led to a dramatic reduction in the U.S. HIV/AIDS death rate.
Recent ENTA News
- Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) • Business Wire • 03/30/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:20:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:18:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:14:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:05:29 PM
- Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference • Business Wire • 03/03/2026 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/23/2026 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:31:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:29:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:28:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:27:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/11/2026 09:43:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:00:44 PM
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting • Business Wire • 02/10/2026 12:00:00 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 • Business Wire • 02/09/2026 09:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2026 09:10:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2026 09:05:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/20/2026 09:42:25 PM
- Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook • Business Wire • 01/08/2026 12:00:00 PM
- Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/05/2026 12:00:00 PM
